Clinical Trial Update: A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing ixekizumab to adalimumab in psoriatic arthritis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Ixekizumab (ixekizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Psoriatic Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2019-04-02